MY115288A - Substituted pyrimidines for control of diabetic complications. - Google Patents

Substituted pyrimidines for control of diabetic complications.

Info

Publication number
MY115288A
MY115288A MYPI93001941A MYPI9301941A MY115288A MY 115288 A MY115288 A MY 115288A MY PI93001941 A MYPI93001941 A MY PI93001941A MY PI9301941 A MYPI9301941 A MY PI9301941A MY 115288 A MY115288 A MY 115288A
Authority
MY
Malaysia
Prior art keywords
diabetic
formula
relates
derivatives
diabetic complications
Prior art date
Application number
MYPI93001941A
Other languages
English (en)
Inventor
Banavara L Mylari
Peter J Oates
Todd W Siegel
William J Zembrowski
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MY115288A publication Critical patent/MY115288A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
MYPI93001941A 1992-09-28 1993-09-23 Substituted pyrimidines for control of diabetic complications. MY115288A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95222292A 1992-09-28 1992-09-28

Publications (1)

Publication Number Publication Date
MY115288A true MY115288A (en) 2003-05-31

Family

ID=25492671

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI93001941A MY115288A (en) 1992-09-28 1993-09-23 Substituted pyrimidines for control of diabetic complications.

Country Status (15)

Country Link
US (2) US5728704A (enExample)
EP (1) EP0662962A1 (enExample)
JP (1) JP2789134B2 (enExample)
KR (1) KR950703539A (enExample)
AU (1) AU683620B2 (enExample)
CA (1) CA2145640C (enExample)
FI (1) FI934224L (enExample)
HU (1) HU220669B1 (enExample)
IL (1) IL107085A (enExample)
MY (1) MY115288A (enExample)
NO (1) NO306598B1 (enExample)
NZ (1) NZ254550A (enExample)
TW (1) TW284759B (enExample)
WO (1) WO1994007867A1 (enExample)
ZA (1) ZA937142B (enExample)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2145640C (en) * 1992-09-28 2001-01-30 Banavara L. Mylari Substituted pyrimidines for control of diabetic complications
ES2114662T3 (es) * 1993-08-26 1998-06-01 Ono Pharmaceutical Co Derivados de la 4-aminopirimidina.
GB9325217D0 (en) * 1993-12-09 1994-02-09 Zeneca Ltd Pyrimidine derivatives
ATE216226T1 (de) * 1996-02-29 2002-05-15 Pfizer Verwendung von sorbitol-dehydrogenase-inhibitoren zum reduzieren von ischämie-assozierten gewebeschäden
DK0970095T3 (da) 1997-03-07 2004-03-08 Metabasis Therapeutics Inc Hidtil ukendte benzimidazolinhibitorer for fructose-1,6-bisphosphase
WO1998039344A1 (en) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
US6054587A (en) * 1997-03-07 2000-04-25 Metabasis Therapeutics, Inc. Indole and azaindole inhibitors of fructose-1,6-bisphosphatase
EP1402895A1 (en) * 1997-03-07 2004-03-31 Metabasis Therapeutics, Inc. Benzimidazole inhibitors of fructose 1,6-biphosphatase
DE19710435A1 (de) * 1997-03-13 1998-09-17 Hoechst Ag Verwendung von Pyrimidinderivaten zur Prävention von Krebs allein oder in Kombination mit anderen therapeutischen Maßnahmen
EA002885B1 (ru) * 1997-04-15 2002-10-31 Ссир Средства растительного происхождения для подавления аппетита
IL124236A (en) * 1997-05-05 2003-01-12 Pfizer Pharmaceutical composition for treating or reversing diabetic cardiomyopathy comprising aldose reductase inhibitor
AU2003242500B2 (en) * 1998-09-09 2006-11-02 Metabasis Therapeutics, Inc. Novel Heteroaromatic Inhibitors of Fructose 1,6-bisphosphatase
CN1900087A (zh) * 1998-09-09 2007-01-24 症变治疗公司 新的果糖1,6－二磷酸酶的杂芳族抑制剂
CN1215076C (zh) * 1998-09-09 2005-08-17 症变治疗公司 新的果糖1,6－二磷酸酶的杂芳族抑制剂
US6756360B1 (en) * 1998-12-24 2004-06-29 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
ES2215570T3 (es) * 1999-04-01 2004-10-16 Pfizer Products Inc. Compuestos para tratar y prevenir complicaciones diabeticas.
AU768720B2 (en) * 1999-04-01 2004-01-08 Pfizer Products Inc. Aminopyrimidines as sorbitol dehydrogenase inhibitors
GB2396815B (en) * 1999-10-27 2004-09-08 Phytopharm Plc A composition comprising a pregnenone derivative and an NSAID
US6380200B1 (en) * 1999-12-07 2002-04-30 Pfizer, Inc. Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
SK8892002A3 (en) * 1999-12-22 2003-04-01 Metabasis Therapeutics Inc Novel bisamidate phosphonate prodrugs, process for their preparation and use thereof
CN1516705A (zh) * 2000-03-08 2004-07-28 ֢�����ƹ�˾ 新的芳基果糖-1,6-二磷酸酶抑制剂
US7563774B2 (en) 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
DK1335906T3 (da) * 2000-11-10 2007-02-05 Hoffmann La Roche Pyrimidinderivater og anvendelse deraf som neuropeptid Y-receptorligander
ES2230378T3 (es) * 2000-11-30 2005-05-01 Pfizer Products Inc. Combinacion de agonistas de gaba e inhibidores de sorbitol deshidrogenasa.
AP2001002359A0 (en) * 2000-11-30 2001-12-31 Pfizer Prod Inc Combination of gaba agonists and aldose reductase inhibitors.
US6555573B2 (en) * 2000-12-21 2003-04-29 The Quigley Corporation Method and composition for the topical treatment of diabetic neuropathy
US7081470B2 (en) 2001-01-31 2006-07-25 H. Lundbeck A/S Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
US20040127502A1 (en) * 2001-01-31 2004-07-01 Synaptic Pharmaceutical Corporation Use of GAL3 antagonist for treatment of depression
EP1247809A3 (en) 2001-03-30 2003-12-17 Pfizer Products Inc. Triazine compounds useful as sorbitol dehydrogenase inhibitors
US6825198B2 (en) 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
AU2002341257A1 (en) * 2001-10-15 2003-04-28 Pfizer Products Inc. Three dimensional crystal structure of human sorbitol dehydrogenase and uses thereof
US20030105027A1 (en) * 2001-11-06 2003-06-05 Rosenbloom Richard A. Nutritional supplements and methods for prevention, reduction and treatment of radiation injury
US7435725B2 (en) * 2001-11-06 2008-10-14 The Quigly Corporation Oral compositions and methods for prevention, reduction and treatment of radiation injury
BR0306988A (pt) * 2002-01-18 2004-11-23 Pharmacia Corp Piridazinonas substituìdas como inibidores de p38
EP1483247B1 (en) 2002-03-13 2009-06-24 Euro-Celtique S.A. Aryl substituted pyrimidines and the use thereof
WO2004000318A2 (en) * 2002-06-21 2003-12-31 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
AU2003245669A1 (en) * 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain aromatic monocycles as kinase modulators
US7083813B2 (en) * 2002-11-06 2006-08-01 The Quigley Corporation Methods for the treatment of peripheral neural and vascular ailments
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
AU2005244450B2 (en) * 2004-05-19 2010-08-19 Solvay Pharmaceuticals Gmbh Medicaments containing N-sulfamoyl-N'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions
US20050261292A1 (en) * 2004-05-19 2005-11-24 Solvay Pharmaceuticals Gmbh Pharmaceutical composition containing N-sulfamoyl-N'-arylpiperazines for the treatment or inhibition of obesity and related conditions
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
GB0415364D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
RU2007102288A (ru) * 2004-08-18 2008-09-27 Мебабазис Терапеутикс, Инк. (Us) Новые тиазольные ингибиторы фруктозо-1,6-бисфосфатазы
EP1796673A2 (en) * 2004-09-23 2007-06-20 Reddy US Therapeutics, Inc. Novel pyrimidine compounds, process for their preparation and compositions containing them
BRPI0518300A2 (pt) * 2004-11-23 2008-11-11 Warner Lambert Co derivados de Ácido 7-(2h-pirazol-3-il)-3,5-diidràxi-heptanàico como inibidores da hmg co-a reductase para o tratamento de lipidemia
BRPI0519013A2 (pt) * 2004-12-13 2009-11-03 Lilly Co Eli composto ou esteroisÈmeros únicos, misturas de esteroisÈmeros, sais, tautÈmeros ou pró-drogas destes farmaceuticamente aceitáveis, composição farmacêutica, e, uso de um composto
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7863446B2 (en) * 2006-01-19 2011-01-04 Orchid Research Laboratories Limited Heterocycles
CN101360717B (zh) * 2006-01-19 2014-04-16 幽兰化学医药有限公司 包含嘧啶环的化合物
US8158667B2 (en) * 2006-08-21 2012-04-17 Kador Peter F Topical treatment of cataracts in dogs
CN101663262B (zh) 2006-12-01 2014-03-26 百时美施贵宝公司 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
US20090018151A1 (en) * 2007-02-23 2009-01-15 Ezekiel Fink Topical Treatment of Peripheral diabetic complications
US8877717B2 (en) 2007-03-12 2014-11-04 Zadec Aps Anti-diabetic extract of rooibos
NZ580266A (en) 2007-04-27 2012-03-30 Purdue Pharma Lp Trpv1 inhibitors / antagonists and uses thereof
WO2009095773A2 (en) 2008-02-01 2009-08-06 Orchid Research Laboratories Limited Novel heterocycles
EP2571860A1 (en) 2010-05-21 2013-03-27 Pfizer Inc 2-phenyl benzoylamides
US8916563B2 (en) 2010-07-16 2014-12-23 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
EP2680874A2 (en) 2011-03-04 2014-01-08 Pfizer Inc Edn3-like peptides and uses thereof
LT2723732T (lt) 2011-06-22 2017-02-27 Purdue Pharma Lp Trpv1 antagonistai, įskaitant dihidroksi pakaitą, ir jų panaudojimas
WO2014170786A1 (en) 2013-04-17 2014-10-23 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
SI3352754T1 (sl) 2016-06-21 2021-03-31 The Trustees Of Columbia University In The City Of New York Zaviralci aldozne reduktaze in postopki njihove uporabe
EP3658142B1 (en) 2017-07-28 2024-04-17 Applied Therapeutics, Inc. Compositions and methods for treating galactosemia
CN108101883B (zh) * 2018-01-31 2018-11-13 佳木斯大学附属第一医院 一种用于防治糖尿病视网膜病变的药物及其制备方法
AU2020209215B2 (en) 2019-01-18 2023-02-02 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
CA3132136A1 (en) 2019-04-01 2020-10-08 Andrew Wasmuth Inhibitors of aldose reductase
CA3136100A1 (en) 2019-05-07 2020-11-12 Stephan L. ZUCHNER Treatment and detection of inherited neuropathies and associated disorders

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1063014A (fr) * 1950-06-14 1954-04-29 Wellcome Found Dérivés de pyrimidine et leur préparation
GB959699A (en) * 1961-06-09 1964-06-03 May & Baker Ltd New pyrimidine derivatives
US4130714A (en) * 1977-05-23 1978-12-19 Pfizer Inc. Hydantoin therapeutic agents
IE47592B1 (en) * 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
FR2489141A1 (fr) * 1980-09-03 1982-03-05 Sevifra Appareil chirurgical pour la decoupe precise de la cornee
DOP1981004033A (es) * 1980-12-23 1990-12-29 Ciba Geigy Ag Procedimiento para proteger plantas de cultivo de la accion fitotoxica de herbicidas.
CA1176269A (en) * 1981-03-02 1984-10-16 Kazimir Sestanj N-naphthoylglycine derivatives
US4864028A (en) * 1983-09-14 1989-09-05 Alcon Laboratories, Inc. Spiro-tricyclicaromatic succinimide derivatives
US5066659A (en) * 1984-10-30 1991-11-19 Pfizer Inc. Spiro-heteroazalones for treatment of diabetic complications
US5102908A (en) * 1985-03-15 1992-04-07 Michael Albeck Method of treating Acquired Immunedeficiency Syndrome (AIDS) using organic tellurium and selenium derivatives
GB8524663D0 (en) * 1985-10-07 1985-11-13 Fujisawa Pharmaceutical Co Quinazoline derivatives
JPH0637473B2 (ja) * 1985-10-11 1994-05-18 三共株式会社 ラクタム化合物
US4939140A (en) * 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
US4835410A (en) * 1988-02-26 1989-05-30 Black & Decker Inc. Dual-mode corded/cordless system for power-operated devices
GB8810203D0 (en) * 1988-04-29 1988-06-02 Ici Plc Heterocyclic compounds
GB8902405D0 (en) * 1989-02-03 1989-03-22 Ici Plc Heterocyclic compounds
DE3905364A1 (de) * 1989-02-22 1990-08-23 Hoechst Ag Substituierte pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als tool
US4996204A (en) * 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
US5039672A (en) * 1990-04-05 1991-08-13 Pfizer Inc. Heterocyclic compounds as aldose reductase inhibitors
US5098904A (en) * 1990-06-27 1992-03-24 Bristol-Myers Squibb Company Cerebral function enhancing pyrimidinyl derivatives
GB9016984D0 (en) * 1990-08-02 1990-09-19 Ici Plc Aniline derivatives
DE4025387A1 (de) * 1990-08-10 1992-02-13 Hoechst Ag Substituierte pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als reagenzien
CA2090027A1 (en) * 1990-08-31 1992-03-01 Shoichi Chokai Pyrimidine derivatives and drugs
CA2145640C (en) * 1992-09-28 2001-01-30 Banavara L. Mylari Substituted pyrimidines for control of diabetic complications

Also Published As

Publication number Publication date
FI934224A0 (fi) 1993-09-27
IL107085A0 (en) 1993-12-28
FI934224A7 (fi) 1994-03-29
AU683620B2 (en) 1997-11-20
CA2145640A1 (en) 1994-04-14
FI934224L (fi) 1994-03-29
US5866578A (en) 1999-02-02
ZA937142B (en) 1995-03-23
CA2145640C (en) 2001-01-30
HU9302734D0 (en) 1993-12-28
HUT65531A (en) 1994-06-28
TW284759B (enExample) 1996-09-01
EP0662962A1 (en) 1995-07-19
NO306598B1 (no) 1999-11-29
HU220669B1 (hu) 2002-04-29
US5728704A (en) 1998-03-17
KR950703539A (ko) 1995-09-20
NO951155L (no) 1995-05-26
WO1994007867A1 (en) 1994-04-14
JP2789134B2 (ja) 1998-08-20
NZ254550A (en) 1997-08-22
IL107085A (en) 2001-01-11
JPH07507072A (ja) 1995-08-03
NO951155D0 (no) 1995-03-27
AU4669793A (en) 1994-04-26

Similar Documents

Publication Publication Date Title
MY115288A (en) Substituted pyrimidines for control of diabetic complications.
MY136039A (en) Sorbitol dehydrogenase inhibitors
BG103964A (en) SUBSTITUTED PYRAZOLS AS p38 KINASE INHIBITORS
WO2002046170A8 (en) Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto
CA2195129A1 (en) Substituted piperidine intermediates for producing heterocyclic-cyclic amine derivatives capable of inhibiting cholinesterase
ZA200508830B (en) Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors
PL348769A1 (en) 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents
CA2085037A1 (en) Stabilized pharmaceutical compositions comprising an hmg-coa reductase inhibitor compound
MY103906A (en) 1-nitro-2, 2-diaminoethylene deravatives
IL114315A0 (en) Heterocyclic compounds and pharmaceutical compositions containing the same for inhibiting phosphodiesterase IV
IL104024A (en) 4-pyrimidinyl and pyridinyl derivatives of indol-3-yl- alkyl piperazines and antimigraine pharmaceutical compositions containing them
AU8680291A (en) An aminoglycoside composition having substantially reduced nephrotoxicity induced by the amino glycoside
MXPA04002423A (es) Derivados de piperazina con actividad antagonista del receptor ccr1.
SG47626A1 (en) Substituted pyrimidines
IL136359A (en) Dihydrobenzofuran substituted phthalazin-1-one derivatives and pharmaceutical compositions containing the same
TR200002466T2 (tr) Azetidin ve pirolidin türevleri
NO984470L (no) Pyrrolopyrrolon-derivater som inhibitorer for neutrofil elastase
EG20726A (en) Process for preparing of galanthamine derivatives as acetylchol inc-sterase inhibitors
DK0547545T3 (da) Farmaceutisk præparat til inhibering af knogleresorption
DK0708093T3 (da) Quinoxaliner, fremgangsmåde til fremstilling deraf og deres anvendelse
NZ222640A (en) Quinolinol derivatives and pharmaceutical compositions
EP0516860A4 (en) Chromone derivative and aldose reductase inhibitor containing the same as active ingredient
WO1992006954A3 (en) Pyrrolidine dione derivatives
ID22762A (id) Komposisi untuk mengobati atau mencegah kanker prostat
MY108187A (en) Stabilized pharmaceutical compositions comprising an hmg-coa reductase inhibitor compound